ENB Therapeutics Announces Clinical Trial Collaboration with Merck
Bioharmony Therapeutics and Boehringer Ingelheim Announce Collaboration for MDR Infections
Toggle Accepted in Cohort 5 of Urban X
EpiVax Oncology Appoints CTO & BOD Member
Accelerate NY Seed fund invested $100,000 in cancer drug developer TargaGenix Inc. The company is commercializing a novel chemotherapy agent developed at Stony Brook University.
Click Here to to Read More